Sarcopenia in older adults with acute ischemic stroke
Official title: Sarcopenia in Patients During the Acute Phase of Ischemic Stroke: Multimodal Assessment and Three-Month Functional Outcomes
Run by University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) · NCT07764172 · Data updated 2026-11-12
This study tests how common sarcopenia is in people 50 and older after an acute ischemic stroke and whether having sarcopenia at hospital admission is linked to worse outcomes three months later.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) Academic / other |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT07764172 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Candidates are adults 50 years or older with a confirmed acute ischemic stroke admitted within 72 hours and who can provide informed consent.
✕Probably not a fit
Patients with conditions or circumstances that prevent sarcopenia assessment or follow-up may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study enrolls adults 50+ with acute ischemic stroke within 72 hours of admission to determine how often sarcopenia occurs and how it progresses during the acute phase using imaging and functional assessments. A subset also undergoes cognitive testing to explore links between sarcopenia, cognition, and recovery. The main question is whether sarcopenia at admission is associated with higher complications or mortality and poorer functional outcomes at three months. Data will come from standard medical care with extended assessments specifically for sarcopenia. No interventional treatments are administered as part of the study.
Why it matters
Potential benefit: If sarcopenia is linked to poorer outcomes, findings could guide closer monitoring and tailored rehabilitation for stroke patients.
How similar studies have gone: Some prior work suggests sarcopenia is associated with worse outcomes after stroke, but this study adds prospective, observational data in the acute phase with formal assessments.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 50 years and older * Acute ischemic stroke confirmed by CT or MRI * Admission within the first 72 hours * Written informed consent and availability of a contact telephone number for follow-up Exclusion Criteria: * TIA without a visible lesion on neuroimaging; bilateral hemiparesis * Amputations or severe contractures that preclude anthropometric assessment * Active cancer at stage IV or life expectancy of less than 3 months * Neuromuscular diseases; chronic use of systemic glucocorticoids for more than 3 months * Pregnancy; refusal to participate Discontinuation criteria (drop-out) * Discharge or death within the first 7 days * Withdrawal of consent * Transfer to another facility resulting in loss of contact
Where it's running
-
Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"
Moscow, Russia Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
-
Bone marrow mesenchymal stem cell injection for sarcopenia
This study tests whether CG-BM1, a stem cell injection, can be safely given to adults with sarcopenia to see if it helps improve muscle health.
-
GLP-1 receptor agonist use and muscle health in adults with obesity without diabetes
This study tests whether GLP-1 receptor agonists affect muscle mass and strength in adults with obesity who don’t have diabetes.
-
Sarcopenia and Epidural Steroid Injections in Lumbar Spinal Stenosis
We’re testing how sarcopenia relates to pain, function, and quality of life after a routine interlaminar epidural steroid injection in people with lumbar spinal stenosis.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
-
Lower-limb rehabilitation robot training with nutrition education for sarcopenia
In adults aged 60 and older with sarcopenia, this study tests whether adding robot-assisted leg training to nutrition education can improve muscle mass and walking ability compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.